SAN FRANCISCO, Nov. 16, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced that Matthew R. Patterson,
President and Chief Executive Officer, will present at the
following upcoming investor conferences:
- Piper Jaffray Healthcare Conference
November 28, 2017, 11:00 am ET
Lotte New York Palace, New York,
NY
- Evercore ISI Biopharma Catalyst/Deep Dive Conference
November 29, 2017, 11:45 am ET
Boston Harbor Hotel, Boston,
MA
To access a live webcast of the presentations, please visit the
Events & Presentations page within the Investors & News
section of the Audentes website. Replays of live webcasts
will be available on the Audentes website for approximately 30 days
following the conferences.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology
company focused on developing and commercializing gene therapy
products for patients living with serious, life-threatening rare
diseases. We are currently conducting a Phase 1/2 clinical
study of our lead product candidate AT132 for the treatment of
X-Linked Myotubular Myopathy (XLMTM) and have three additional
product candidates in development, including AT342 for the
treatment of Crigler-Najjar Syndrome, AT982 for the treatment of
Pompe disease, and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300557417.html
SOURCE Audentes Therapeutics, Inc.